Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

RTW Biotech Opportunities: Is the Life Sciences Investment Trust Still a Compelling Bet?

RTW Biotech Opportunities is managed by RTW Investments, a specialist life sciences investment firm. The trust provides listed market investors with access to a portfolio of private and public biotech companies, typically at earlier stages of development than would be found in broad healthcare …

Divya Sood | 28 October 2026

Can Abingdon Health Turn Faster Growth Into Sustainable Progress? (LSE:ABDX)

Its 13 October FY2026 update reported revenue growth and a stronger second half, including progress to adjusted EBITDA profitability in H2. Investors will want to see whether that momentum is repeatable and converts into sustainable cash generation.

Ankur Sharma | 28 October 2026

Cambridge Cognition: Clinical Trial Demand and Cash Conversion in Focus (LSE:COG)

Clinical-trial activity, contract wins, conversion of the order book into revenue and cash usage are important. No verified same-day catalyst was identified in the research available for this article.

Ankur Sharma | 28 October 2026

Eden Biosolutions: Commercial Validation Is the Key Milestone (LSE:EDEN)

Commercial validation, regulatory approvals, repeat customers and cash runway matter more than early-stage market potential alone. No verified same-day catalyst was identified in the research available for this article.

Ankur Sharma | 28 October 2026

Sareum’s Fundraising Puts Clinical Progress Back in the Spotlight (LSE:SAR)

Sareum is in focus after its October fundraising and retail offer. The company reported that the retail offer closed early, following a subscription of approximately £3.2 million announced on 26 October. Investors will watch admission of new shares, cash runway, SDC-1801 development and year-end …

Ankur Sharma | 28 October 2026

Can 4basebio PLC Convert Scientific Progress Into Commercial Momentum on AIM? (LSE:4BB)

- Sector context: Healthcare and AIM-listed healthcare and life-sciences shares.

Ankur Sharma | 28 October 2026

Can EDX Medical Group PLC Convert Scientific Progress Into Commercial Momentum on AIM? (LSE:EDX)

- Sector context: Healthcare and AIM-listed healthcare and life-sciences shares.

Ankur Sharma | 28 October 2026

Can Fusion Antibodies Plc Convert Scientific Progress Into Commercial Momentum on AIM? (LSE:FAB)

- Sector context: Healthcare and AIM-listed healthcare and life-sciences shares.

Ankur Sharma | 28 October 2026

Can GENinCode PLC Convert Scientific Progress Into Commercial Momentum on AIM? (LSE:GENI)

- Sector context: Healthcare and AIM-listed healthcare and life-sciences shares.

Ankur Sharma | 28 October 2026

Can Proteome Sciences plc Convert Scientific Progress Into Commercial Momentum on AIM? (LSE:PRM)

- Sector context: Healthcare and AIM-listed healthcare and life-sciences shares.

Ankur Sharma | 28 October 2026
Support

Hi! How can we help you today?

Loading…